Rectal Adenocarcinoma Clinical Trial
Official title:
Phase II Study of Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced (T3 and T4 or Node Positive) Rectal Adenocarcinoma
Phase II Study of Neo-adjuvant Chemoradiotherapy using infusional Gemcitabine followed by Surgery for Locally Advanced (T3 and T4 or Node positive) Rectal Adenocarcinoma.
Results of neo-adjuvant chemo-radiation for advanced rectal cancer have plateaued with pathological complete response rates of 10-20% in spite of the addition of new cytotoxic agents and/ or molecular targeted therapies. The combination of 5-fluorouracil and radiation produces effective sensitization but further improvements require assessment of other sensitizers to increase the pathological complete response rates. Gemcitabine has been used in combination with radiation for several GI cancers but few studies have examined its role in rectal cancer. This study will examine a combination of Gemcitabine and radiation as neo-adjuvant therapy in advanced rectal cancer to increase the pathological complete response (pCR) rate from the investigators traditional 6% to > 40 %. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05081024 -
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
|
||
Not yet recruiting |
NCT04090450 -
Optimisation of Radiotherapy in Rectal Cancer (ORREC)
|
||
Recruiting |
NCT06050447 -
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
|
||
Terminated |
NCT02233595 -
Evaluation of Rectal Cancer Treatment Response Using PET/MRI
|
||
Completed |
NCT02935309 -
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
|
Phase 1 | |
Terminated |
NCT01887509 -
Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology
|
N/A | |
Recruiting |
NCT05746195 -
Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)
|
N/A | |
Active, not recruiting |
NCT03365882 -
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT02314182 -
GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis
|
Phase 3 | |
Completed |
NCT02393755 -
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04441580 -
Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in a Screening Setting
|
N/A | |
Terminated |
NCT03527784 -
Prestoma-Trial for Parastomal Hernia Prevention
|
N/A | |
Completed |
NCT00855946 -
Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy
|
N/A | |
Recruiting |
NCT06328361 -
Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
|
N/A | |
Recruiting |
NCT02107105 -
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
|
||
Terminated |
NCT03300544 -
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03436563 -
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04814784 -
Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
|
||
Recruiting |
NCT05482516 -
Evaluating Novel Therapies in ctDNA Positive GI Cancers
|
Phase 3 | |
Completed |
NCT02368886 -
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 2 |